Introduction
Over the past few years, a number of subcutaneous devices for continuous glucose monitoring (CGM) have been marketed, and are now routinely used in patients with diabetes in order to obtain detailed information about 24-hour glucose profiles [1] . In the hospital, numerous factors influencing glycemic control and possibly leading to glucose excursions out of the desired range, even in non-diabetic subjects, do exist. In such context, a reliable CGM device could help observing the glycaemic levels in these patients not only at defined time-points but continuously, making it possible for physicians and nursing staff to better adjust antihyperglycemic therapy, and promptly react before the patient is exposed to severe hypo-or hyperglycaemia. The feasibility of CGM in hospitalized patients has been demonstrated [2]; however, concerns about the reliability of such CGM data, particularly for subjects whose physiopathological condition compromises the correlation between interstitial fluid and blood compartment, have been raised [3] . In the hospital setting, vascular accesses are granted in the majority of patients, and these could as well be used as an alternative site for continuous glucose monitoring [4] . Aim of the present study was to optimise the performance of an intravascular (IV) microdialysis system resulting from the combination of GlucoMen ® Day (GMD, A. Menarini Diagnostics, Florence, Italy) and MicroEye ® probe (Probe Scientific Ltd., UK) technologies, and to assess point and trend accuracy of the glucose data obtained by microdialysis against venous blood glucose reference measurements. The performance of the system in its subcutaneous (SC) application were also assessed in parallel for comparative purposes.
Methods
The feasibility of a device that could combine Menarini and Probe Scientific expertises was demonstrated via 2 clinical trials, both of which carried out at the Medical University of Graz (Austria). IV and SC microdialysis were run in parallel for comparative purposes. Peripheral veins of the forearm were accessed through standard IV catheters, while the subcutaneous abdominal tissue by means of a standard splittable introducer. Having no glucose biosensor placed downstream of the microdialysis probe, aim of the first trial (GMD_04) was to assess and optimise the recovery performance of the MicroEye ® probe. In particular, for optimal pairing with the GlucoMen ® Day glucose biosensor technology, relatively low recovery rates of (10 ± 3)% did represent the target performance. 20 healthy subjects underwent monitoring for up to 24 hours. IV and SC dialysate samples were collected in 15 min fractions; reference blood samples were also withdrawn every 15 min (every 30 min during night time); both dialysates and reference plasma samples were then analysed for glucose using a YSI 2300 STAT Plus analyzer. Aim of the second study (GMD_05) was to assess and optimise the overall performance of an intravascular CGM device based on GlucoMen ® Day disposable sensor kits integrating the MicroEye ® probe. With the purpose of challenging the system, 14 T1DM subjects were enrolled in this trial, where CGM (1 data/min) was performed over 72 hours. Throughout the whole study period, the frequency of reference blood sampling remained unchanged, with 1 reference glucose value every 15 min. All subjects underwent routine thrombosis prophylaxis, with 1 SC injection of a low molecular weight anticoagulant every 24 hours. Small concentrations of the same anticoagulant were also included in the formulation of the perfusion solution. Calibration of IV and SC dialysates and CGM data was performed retrospectively, once every 6 (or more) hours.
Results

GMD_04 trial.
As expected, the IV microdialysis approach offered a number of advantages over the SC one. Reliability and stability of the glucose % recovery performance of the IV probe, for example, largely exceeded that of the SC device. The remarkably higher point accuracy of the IV dialysate glucose data clearly emerged from both linear regression and BIAS plot analyses (mean absolute relative error = 5.7%). Use of either one or the other compartment as the glucose sampling site also resulted in a significantly higher trend accuracy (mean absolute rate deviation: 0.27 [IV] vs. 0.45 [SC] mg/dL/min). The IV microdialysis approach additionally allowed to achieve the target glucose % recovery in combination with higher perfusion solution flow rates (which translated in shorter instrumental delays, ≤ 2 min).
GMD_05 trial. As the major difference to the GMD_04 study, disposable sensor kits integrating the GlucoMen ® Day glucose biosensor downstream of the microdialysis probe were employed. Features of such redoxmediated GOD-based biosensor are minimal signal drift, excellent accuracy (particularly in the hypo range), and relatively short run-in time. Interference from a number of endogenous and exogenous chemicals, including the most common electrochemically active drugs, was additionally ruled out [5] . As exemplified in Figure 1A , the IV probes confirmed a remarkably stable glucose % recovery performance throughout the whole monitoring period (72 hours). Occasional fluctuations of the % recovery were attributed to a combination of: clotting at the surface of the microdialysis probe membrane, changes in the position of the probe within the vessel, changes in local blood circulation. A typical CGM profile is shown in Figure 1B . 
Discussion
The MicroEye ® probe exhibited good performance in both the IV and the SC application; however, reliability of the IV microdialysis approach and accuracy of the resulting dialysate glucose data were significantly higher. Different veins of the forearm were accessed with substantially identical results. The target glucose % recovery (i.e., 10%) was achieved at optimised perfusion solution flow rates, and found to be stable for up to 72 hours. 
